CDT Equity Announces 1-for-25 Reverse Stock Split

CDT Equity ( (CDT) ) has issued an update.

On March 24, 2026, CDT Equity Inc. filed a certificate of amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock, effective March 26, 2026, at 5:00 p.m. Eastern Time. The move followed prior shareholder approval authorizing the board to set the timing and ratio, with CDT’s shares expected to begin trading on a split-adjusted basis on Nasdaq under the existing ticker on March 27, 2026.

At the effective time, every 25 issued and outstanding common shares will be combined into one share, leaving the par value unchanged at $0.0001 and reducing the outstanding share count to roughly 4.7 million. Proportional adjustments will be made to equity awards, convertible securities and warrants, fractional shares will be settled in cash and the stock will continue trading on Nasdaq under a new CUSIP, simplifying the capital structure and potentially supporting compliance with listing standards.

Continental Stock Transfer & Trust Co. has been appointed as exchange agent, and registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares. Investors holding CDT in brokerage or street name accounts will see their positions automatically adjusted in line with the reverse split, with no operational changes required from them as the company executes the consolidation of its equity base.

More about CDT Equity

CDT Equity Inc. (Nasdaq: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Evolving from its origins as Conduit Pharmaceuticals, it leverages artificial intelligence, solid-form chemistry and asset repositioning to accelerate novel treatments and pursue value through licensing and strategic M&A.

The company aims to operate as a flexible platform for transformative drug development, concentrating on efficient progression of product candidates rather than end-to-end commercialization. Its model targets opportunities where repositioning or enhancement of existing assets can shorten time to key clinical and regulatory milestones, aligning shareholder returns with an asset-light, partnership-driven approach.

Average Trading Volume: 675,379

Technical Sentiment Signal: Sell

Current Market Cap: $2.15M

For detailed information about CDT stock, go to TipRanks’ Stock Analysis page.